Correlation of Vitamin D Levels with Pigmentation in Vitiligo Patients Treated with NBUVB Therapy
ISRN Dermatology, Volume 2014 (2014), Article ID 493213, 6 pages, http://dx.doi.org/10.1155/2014/493213
Manu Sehrawat,1 Tarlok Chand Arora,1 Amrita Chauhan,1 Hemanta Kumar Kar,1 Amitabh Poonia,2 and Vijayeeta Jairath2
1PGIMER, Dr. RML Hospital, New Delhi, India
2Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana 124001, India
Cholecalciferol (vitamin D) might play a physiological role in photo-induced melanogenesis in human skin. We estimated the levels of 25-hydroxy vitamin D [25(OH)D] before, during, and after Narrow Band Ultraviolet B (NBUVB) radiation in patients of vitiligo and their correlation with NBUVB induced pigmentation. Thirty patients of vitiligo and equal number of age and sex matched controls were recruited for the study. Vitiligo patients were treated with NBUVB thrice weekly for 12 weeks. [25(OH)D] levels and Vitiligo Area and Severity Index (VASI) were calculated at 0 (baseline), 6, and 12 weeks. Baseline [25(OH)D] levels were measured in controls. Significant reduction in VASI score was observed after 12 weeks of therapy. Comparison and correlation between mean improvement in VASI and [25(OH)D] levels at 12 weeks showed moderate correlation, and the results were statistically insignificant. Mean reduction in VASI and increase in [25(OH)D] levels after 12 weeks of NBUVB showed moderate correlation. Thus, vitamin D might play a significant role in photo-induced melanogenesis. However, there might be additional effects of the phototherapy on melanogenesis. The complete mechanism of NBUVB induced pigmentation in vitiligo needs to be elucidated.
A 2nd article in July 2014
Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies.
J Eur Acad Dermatol Venereol. 2014 Jul 30. doi: 10.1111/jdv.12619. [Epub ahead of print]
Yazdani Abyaneh M1, Griffith RD, Falto-Aizpurua L, Nouri K.
1Department of Dermatology and Cutaneous Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, FL, 33136, USA.
Vitiligo is a disorder of pigmentation affecting about 1% of the global population. It is a psychologically devastating disease with suboptimal treatment options. Narrowband ultraviolet B (NB-UVB) phototherapy has become a first-line choice for treating generalized disease. In recent years, topical calcineurin inhibitors, vitamin D analogues, antioxidant agents and other therapies have been combined with NB-UVB to improve its efficacy. This article will address what is known about the mechanisms of action of these treatments and how they may complement NB-UVB on a cellular level, as well as offer a comprehensive, evidence-based review of clinical outcomes with combination therapies.
© 2014 European Academy of Dermatology and Venereology.
Publisher provides low-cost access to the PDF
See also VitaminDWiki
- Beneficial effects of UV radiation other than via vitamin D production – June 2012
- Skin benefits from vitamin D – major overview Feb 2014
- Vitiligo is associated with low vitamin D (nothing about treatment) – meta-analysis March 2016
- 35,000 IU vitamin D daily for 6 months helped ALL psoriasis suffers (106 ng) – Brazil March 2013
Many Vitiligo patients helped by Vitamin D
- Ultraviolet light (which produces vitamin D) decreased the use of psoriasis drugs for a year – Aug 2017
Two out of 16 vitiligo patients showed no repigmentation of the affected areas;
four patients showed 1–25% repigmentation,
five patients showed 26–50% repigmentation,
five patients showed 51–75% repigmentation and
none showed more than 75% repigmentation of the affected areas
See also web
- WikiPedia extensive discussion of UV and Vitiligo
The incidence worldwide is less than 1%
- Comorbidities associated with vitiligo: a ten-year retrospective study 2013
all of the associated diseases were related to low level of vitamin D
thyroid-related, psoriasis, rheumatoid arthritis, alopecia areata, IBD, systemic lupus T1 Diabetes.
Images from the web